Effects of ID-CBT5101 in Preventing and Alleviating Osteoarthritis Symptoms in a Monosodium Iodoacetate-Induced Rat Model
| Autor: | Min-Goo Kim, Dong-Hee Kim, Jongmin Yoon, Boo-Yong Sim, Soobong Park, Dong-Gu Jeong, Joonggu Ji, Hak-Joo Choi, Don-Gil Lee, Dae-Jung Kang, InHwan Joo |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Male medicine.medical_specialty Knee Joint medicine.medical_treatment Arthritis Administration Oral Gene Expression Inflammation Iodoacetates Osteoarthritis Knee Injuries Matrix metalloproteinase Applied Microbiology and Biotechnology Bone and Bones Bone remodeling 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Animals RNA Messenger Saline 030203 arthritis & rheumatology business.industry General Medicine medicine.disease Matrix Metalloproteinases Rats Bacterial vaccine Disease Models Animal 030104 developmental biology medicine.anatomical_structure Endocrinology Bacterial Vaccines Clostridium butyricum Metalloproteases Cytokines Synovial membrane medicine.symptom business Biotechnology |
| Zdroj: | Journal of microbiology and biotechnology. 28(7) |
| ISSN: | 1738-8872 |
| Popis: | Osteoarthritis is a disease that affects the articular cartilage and osseous tissue, and can be worsened by aging, overweight status, and post-traumatic arthritis. The present study aimed to evaluate the effect of ID-CBT5101 (tyndallized Clostridium butyricum) on bone metabolism and the inflammatory response in a monosodium iodoacetate-induced rat model of osteoarthritis. ID-CBT5101 was administered orally at doses of 108 or 1010 CFU/day for 2 weeks before direct injection of monosodium iodoacetate (3 mg/50 μl of 0.9% saline) into the intra-articular space of the rats' right knees. The rats subsequently received the same doses of oral ID-CBT5101 for another 4 weeks. We evaluated the treatment effects based on serum biomarkers, mRNA expression, morphological and histopathological analyses of the knee joints, and weight-bearing distribution analysis. Compared with those in control rats, the ID-CBT5101 treatments significantly reduced the serum concentration of inflammation and bone metabolism markers (i.e., COX-2, IL-6, LTB4, and COMP), and significantly increased the concentration of IFN-γ and glycosaminoglycans. In addition, the ID-CBT5101 treatments inhibited the mRNA expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases (i.e., MMP-2, MMP-3, MMP-9, MMP-13, TIMP-1, and TIMP-2). Furthermore, the ID-CBT5101 treatments effectively preserved the knee cartilage and synovial membrane, and significantly decreased the amount of fibrous tissue. Moreover, compared with that of the negative control group, the ID-CBT5101 treatments increased the weight-bearing distribution by ≥20%. The results indicate that ID-CBT5101 prevented and alleviated osteoarthritis symptoms. Thus, ID-CBT5101 may be a novel therapeutic option for the management of osteoarthritis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|